Ventricular Assist Devices Market By Product (Left Ventricular Assist Devices (LVADs), Right Ventricular Assist Devices (RVADs), Biventricular Assist Devices (BIVADs)), By Application (Bridge-To-Transplant (BTT), Destination Therapy, Bridge-To-Recovery (B

Ventricular Assist Devices Market By Product (Left Ventricular Assist Devices (LVADs), Right Ventricular Assist Devices (RVADs), Biventricular Assist Devices (BIVADs)), By Application (Bridge-To-Transplant (BTT), Destination Therapy, Bridge-To-Recovery (BTR), Bridge To Candidacy Therapy), By Design (Transcutaneous Ventricular Assist Devices, Implantable Ventricular Assist Devices), By Age (Adults, Pediatrics): Global Opportunity Analysis and Industry Forecast, 2024-2035

The ventricular assist devices market was valued at $1.6 billion in 2023 and is estimated to reach $4.1 billion by 2035, exhibiting a CAGR of 8.1% from 2024 to 2035. Ventricular assist device (VAD), also known as mechanical circulatory support (MCS) device, supports the pumping function of the heart. It is used to increase the amount of blood that flows through the patient’s body. It enables a patient with advanced heart failure to lead an improved quality of life once again. A ventricular assist device (VAD) helps in supporting either the right or the left ventricle, however, it is mostly implanted in the left ventricle. When placed in the left ventricle, it is called a left ventricular assist device (LVAD).

Increase in incidences of heart failures is the major factor driving the growth of ventricular assist devices market. There is increase in heart failure cases around the globe owing to various factors such as high prevalence of chronic conditions such as hypertension, diabetes, and obesity. Moreover, factors such as poor lifestyle choices and environmental pollution along with increased stress levels contribute to increase in the number of heart failure cases.  For instance, according to an article published by Centers for Diseases Control and Prevention (CDC), in January 2023, heart disease is the leading cause of death for both men and women in the U.S. and about 6.2 million adults in the U.S. have heart failure. Thus, high incidences of heart failure increases the demand for ventricular assist devices around the globe and thus propels the growth of the market.

In addition, one of the major driving factors of the global ventricular assist devices market is the high prevalence of conditions such as diabetes, atherosclerosis, strokes, hypertension, and other chronic disorders. These conditions mainly arise due to change in lifestyle habits, unhealthy dietary habits, lack of physical activity, and smoking. This further raises the chances of heart failure in the patient and thus increases the demand for ventricular assist devices. Hence, such factors are expected to boost the growth of the market.

The global ventricular assist devices market is segmented into product, application, design, age, and region. By product, the market is categorized into left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), and biventricular assist devices (BIVADs). On the basis of application, the market is fragmented into bridge-to-transplant (BTT), destination therapy, bridge-to-recovery (BTR), and bridge to candidacy therapy. On the basis of design, the market is bifurcated into transcutaneous ventricular assist devices and implantable ventricular assist devices. By age, the market is divided into adults and pediatrics. Region-wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, North Africa, Middle East & Africa).

The key players that operate in the ventricular assist devices market are Abbott Laboratories, Abiomed, Inc., AdjuCor GmbH, Berlin Heart GmbH, Bivacor Inc., Calon Cardio-Technology Ltd, Carmat SA, CH Biomedical, Inc., Corewave SA, Evaheart, Inc., Fineheart, Jarvik Heart, Inc., LivaNova PLC, NuPulseCV, Inc., SynCardia Systems, LLC, and Windmill Cardiovascular Systems. The key players have adopted product launch, product development, and product approval as the key strategies to strengthen their foothold in the competitive market.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the ventricular assist devices market analysis from 2023 to 2035 to identify the prevailing ventricular assist devices market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the ventricular assist devices market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global ventricular assist devices market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Application

Bridge-To-Transplant (BTT)
Destination Therapy
Bridge-To-Recovery (BTR)
Bridge To Candidacy Therapy

By Design

Transcutaneous Ventricular Assist Devices
Implantable Ventricular Assist Devices

By Age

Adults
Pediatrics

By Product

Left Ventricular Assist Devices (LVADs)
Right Ventricular Assist Devices (RVADs)
Biventricular Assist Devices (BIVADs)

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Evaheart, Inc.
Abiomed, Inc.
Abbott Laboratories
CH Biomedical, Inc.
Carmat SA
Bivacor Inc.
LivaNova PLC
Berlin Heart GmbH
Fineheart
AdjuCor GmbH

Please Note: It will take 7-10 business days to complete the report upon order confirmation.